Company intelligence / Profile preview

CytoTronics

Boston, Massachusetts, United Statescytotronics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

CytoTronics has launched its Pixel system, a high-throughput semiconductor-based platform that enables real-time, multiplexed live-cell analysis at single-cell resolution. The system is being adopted by biopharma companies and academic researchers for applications in drug discovery, phenotypic screening, toxicity assays, immuno-oncology, cardiotoxicity testing, neuroscience applications, and more. The company is currently commercializing the product with ongoing expansion into high-throughput screening capabilities.

Therapeutic areas: OtherCardiovascularOncologyNeurology
Modalities: DevicePlatform (semiconductor-based live-cell analysis)
Industry: Pathology

Partnerships

No specific major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on CytoTronics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CytoTronics.

Explore the full profile